DeepValue | The New Way Investors Work

Hims & Hers has become one of the most visible consumer-health names in the market, thanks to aggressive marketing, GLP-1 weight-loss buzz, and a high-profile push into diagnostics and lab testing. At a recent price of about $24.26, the stock is no longer trading like a speculative telehealth startup. It’s priced more like a scaled consumer platform that is expected to stay profitable and grow through heavy scrutiny.

From our perspective at DeepValue, the key question isn’t “Is this a real business?”—that has already been answered. Revenue reached $1.48 billion in 2024 with 79% gross margins and $198 million of free cash flow, and Q3 2025 alone delivered roughly $599 million in revenue and $78 million of adjusted EBITDA with a 13% margin, according to the 10-Q (2025). The real debate is whether today’s valuation fairly discounts the structural shift away from shortage-enabled GLP-1 compounding toward a broader platform of subscriptions, labs, and chronic-care offerings.

We currently rate the stock WAIT. There is a solid business here, but the next two quarters need to prove that Hims & Hers can defend its unit economics and earnings power as regulatory tailwinds fade and fixed costs rise from vertical integration.

If you’re trying to decide whether to build or add to a position, Q1–Q2 2026 will be pivotal.

Within our own process, we rely on automation to move fast across complex names like this—parsing 10-Ks, Qs, and industry coverage in minutes instead of days. If you want to do the same and scale your own deep dives beyond a handful of tickers, Read our AI-powered value investing guide. It walks through exactly how investors are using tools like DeepValue to go from raw filings to structured, citation-backed theses without drowning in PDFs.

Use our deep research engine to recreate this full HIMS thesis in minutes, with every claim tied back to SEC filings and niche industry sources for “trust but verify” due diligence.

Run Deep Research on HIMS →

Hims & Hers in 2026: What Exactly Is the Market Pricing In?

At around $24, the market cap sits near $5.3 billion with a P/E of roughly 41 and an EV/EBITDA multiple near 76.9, based on FMP data summarized in our report. That’s a rich multiple for any healthcare platform—especially one navigating a meaningful regulatory reset.

According to the 10-K (2025), Hims & Hers has evolved from a simple telehealth front-end into a vertically integrated operator. It now owns:

Large mail-order pharmacies (XeCare in Ohio, Apostrophe in Arizona)
A 503B outsourcing facility (MedisourceRx)
A peptide manufacturing facility
A lab testing facility

This build-out underpins the story investors are now buying: a consumer-first subscription platform with owned infrastructure, not just a marketing layer on top of third-party pharmacies.

The problem is that this infrastructure also raises fixed costs. When the regulatory backdrop was more forgiving and semaglutide shortages allowed compounding at scale, those fixed costs looked like an easy investment. But the FDA has since declared the national semaglutide shortage resolved and ended shortage-based enforcement discretion for compounded GLP-1s: 503A by April 22, 2025 and 503B by May 22, 2025, as outlined in the FDA policy clarification (Apr 28 2025).

Management itself acknowledges that this has already constrained and is expected to continue constraining access to compounded semaglutide, per the 10-Q (2025). That raises the bar for what the platform must achieve in non-GLP-1 categories and within Labs/diagnostics to keep justifying today’s valuation.

Our base, bull, and bear scenarios reflect this balancing act:

Base case (50% probability): Implied value around $28
Bear case (30% probability): Implied value around $16
Bull case (20% probability): Implied value around $40

In the base case, marketing efficiency holds near recent levels and subscribers grow in the mid-teens with adjusted EBITDA margins around 12%. In the bear case, semaglutide rules bite harder, ARPU dips below $70, and margins compress toward 8%. The bull case assumes Labs attach and renewals meaningfully lift recurring revenue per subscriber while margins expand to 14%.

At today’s price, we see very little valuation-based margin of safety. The margin of safety, such as it is, comes from the balance sheet: over $1.1 billion of cash and investments plus net cash of roughly $209 million, alongside a $250 million buyback authorization running through 2028, as disclosed in the 8-K (2025).

That liquidity can buffer a period of volatility. But it does not protect equity holders if the business model itself is impaired by regulation or deteriorating marketing economics.

Is HIMS Stock a Buy in 2026?

We think the honest answer is: not yet, for disciplined value investors.

Let’s unpack why.

Strong fundamentals… on a changing foundation

Fundamentals going into 2026 are undeniably strong. According to the 10-K (2025):

2024 revenue: $1.4765 billion
2024 Online Revenue: $1.4379 billion
2024 gross margin: 79% (down from 82% as integration investments ramped)
2024 net income: $126 million
2024 Adjusted EBITDA: $176.9 million
2024 operating cash flow: $251.1 million
2024 free cash flow: $198.3 million

By Q3 2025, momentum remained robust. The 10-Q (2025) shows:

Q3 2025 revenue: $598.976 million
Q3 2025 adjusted EBITDA: $78 million (13% margin)
Subscribers: about 2.47 million
Monthly Online Revenue per Average Subscriber: $80, up from $64 in 2024 and $54 in 2023

Personalized offerings accounted for about 70% of Online Revenue in Q3 2025, and those offerings—plus weight loss—have lifted ARPU significantly. Management has also delivered on profitability: Q1 2025 alone generated $586 million of revenue, $49.5 million of net income, and $91.1 million of adjusted EBITDA, as detailed in the Q1 2025 earnings release (May 5 2025).

So why aren’t we pounding the table?

Because the driver of that ARPU expansion and profitability mix is in flux. The same FDA regime that allowed compounding to flourish is now normalizing, while scrutiny on advertising and promotional claims for weight-loss drugs is intensifying, as highlighted by AP News coverage of enforcement (Oct 2025) and The Dallas Morning News (Sep 2025).

We want to see the business prove that:

1. Subscribers keep growing in the mid-teens or better,

2. ARPU remains near $80 (or at least doesn’t retrace sharply lower), and

3. Adjusted EBITDA margins stay above 10–12%,

without relying on relaxed compounding rules or unsustainably cheap customer acquisition.

Marketing efficiency is the clearest near-term test

Hims & Hers is leaning into mass media and large campaigns, including Super Bowl-scale advertising with cultural messaging that positions the brand against perceived inequality, as reported by Business Insider (Jan 2026) and AP News’ Super Bowl ad preview (Feb 2026).

That’s great for awareness, but expensive brand wars can be brutal on CAC if conversion doesn’t keep up. Management itself has framed marketing as a key efficiency lever: in Q3 2025, marketing spend was about 39% of revenue, which they described as more than six points of year-over-year leverage, according to the Q3 2025 earnings call transcript (Nov 3 2025).

Our 90-day checkpoint (into roughly May 2026) is simple:

If marketing as a % of revenue is flat to down versus 39% and
Sequential net subscriber adds accelerate above Q3 2025’s >30,000,

we become more comfortable leaning into the name. If, instead, marketing creeps higher and net adds stagnate around 30k or less, we would treat that as a signal to size down or stay sidelined.

That’s the crux of our “WAIT” rating: we need actual data, not stories, to validate that the new marketing-heavy playbook still delivers attractive LTV/CAC under a tighter regulatory regime.

Mid-article is often where investors want to dive deeper into numbers across multiple ideas, not just one. If you’re juggling several telehealth or consumer-health names,

Use [DeepValue](https://app.deepvalue.tech/) to run 10+ tickers like HIMS in parallel, each with standardized, citation-backed reports so you can compare marketing efficiency, ARPU, and margin trajectories without getting lost in filings.

Research HIMS in Minutes →

Will Hims & Hers Deliver Long-Term Growth Beyond GLP-1?

The heart of the long-term thesis now lies in platform expansion: labs, diagnostics, chronic specialties, and international growth.

Labs and diagnostics: a second revenue layer

In late 2025, Hims & Hers announced Labs, a holistic in-depth testing initiative designed to create recurring diagnostics subscriptions. Plans are priced at:

$199 per year for one blood draw and roughly 50 biomarkers
$499 per year for two blood draws and 120+ biomarkers

This offering is supported by a national partnership with Quest Diagnostics, as described in the Labs launch release (Nov 13 2025). Then, in early 2026, the company layered on a premium add-on: access to GRAIL’s Galleri multi-cancer early detection test, offered with a $250 discount, per the multi-cancer testing announcement (Feb 4 2026).

For investors, this is the critical pivot:

Labs can lift ARPU by selling diagnostic subscriptions on top of treatment subs
It can improve retention, as customers with regular testing cadence are less likely to churn
It can help reposition Hims & Hers from “GLP-1 telehealth trade” to “holistic health and wellness platform,” which is how outlets like The Washington Post’s health brief (Jan 2026) have increasingly framed the company’s narrative

Our mid-2026 checkpoint is straightforward: by August 2026, we want to see evidence that Labs moves the needle—either through disclosed attach and renewal metrics, or clear proxies like sustained ARPU resilience and a growing mix of personalized solutions.

If Labs is still a PR line item with no measurable economic impact by then, while operating expenses and capex continue rising to support facilities, we would treat that as a red flag.

Diversifying specialties and geographies

Beyond Labs, management’s roadmap includes:

Expanding into recurring-treatment specialties like testosterone, menopause, sleep, PTSD, fertility, diabetes, cholesterol, and hypertension
Scaling UK/EU presence via the ZAVA acquisition (covering the UK, Germany, France, and Ireland), as announced in BusinessWire (Jun 3 2025)

These expansions could help reduce dependence on any one drug class or regulatory environment. But they also add layers of complexity:

Different regulatory regimes across Europe
More SKUs and clinical protocols
Additional fixed costs and integration risk

Our longer-term (2–5 year) view is that Hims & Hers must demonstrate three things to justify a premium multiple:

1. Revenue diversification: GLP-1-related economics should no longer dominate the growth narrative.

2. Stable ARPU and retention: even as management expects ARPU to “normalize over the long term,” the platform has to hold the line without spiking marketing.

3. Regulatory-grade operations: staying compliant across cGMP manufacturing, 503B outsourcing, and CLIA lab environments, especially as scrutiny intensifies.

If the company can pull that off, the bull case toward $40 becomes much more credible. But each of those checkpoints is non-trivial.

Key Risks: What Could Break the HIMS Thesis?

For investors, one of the strengths of Hims & Hers as a research subject is that the failure modes are fairly clear. This isn’t a vague “competition” story; it’s a set of specific regulatory and unit-economics tripwires.

1. Regulatory clampdown on compounding and advertising

The first and most obvious risk is that the FDA goes further on semaglutide and related GLP-1s. If semaglutide is added to the finalized “Demonstrable Difficulties for Compounding List” or if equivalent action effectively prohibits compounding, then a meaningful piece of the current weight-loss economics could vanish.

The FDA’s April 2025 clarification already ended shortage-based enforcement discretion. From here, a stricter stance could force abrupt product withdrawal and drive cancellations, putting both ARPU and margins under pressure.

Advertising is the second regulatory front. Prior enforcement actions and ongoing scrutiny have been covered extensively by AP News (Oct 2025) and The Dallas Morning News (Sep 2025). A major warning letter or settlement that forces Hims & Hers to change marketing practices could materially affect conversion rates and raise CAC.

Our view: these risks are real but bounded. They don’t automatically take the business to zero, but they can reset the earnings power that today’s 40x P/E multiple is built on.

2. Marketing arms race erodes economics

The second major risk is that the category devolves into a full-blown marketing arms race. With high-profile Super Bowl ads and broad-based campaigns, category spend is clearly escalating, as noted by AP News (Feb 2026) and Business Insider (Jan 2026).

When that happens, two things can go wrong for investors:

CAC rises faster than LTV, shrinking the value of each new subscriber
Management feels pressured to keep spending to “defend” brand position, even if the incremental economics are poor

Our thesis-breaker here is clear: two consecutive quarters where marketing as a % of revenue rises versus the 39% Q3 2025 baseline, while net subscriber adds stay around or below 30k. That combination would confirm that the company is spending more just to stand still.

3. Fixed-cost deleverage from vertical integration

The third risk is more subtle but equally important: fixed-cost deleverage.

Hims & Hers has invested heavily in:

Pharmacies
A 503B outsourcing facility
Peptide manufacturing
Lab testing infrastructure
European integration via acquisitions

In theory, vertical integration should reduce per-order costs and increase control over the customer experience. Yet if Labs attach is weak, Europe ramps slowly, or regulatory changes shrink high-margin GLP-1-related revenue, these fixed costs can become a drag on returns rather than a moat.

Management has explicitly warned that if operating cash flow turns negative for multiple quarters, the company may need additional financing that “may be dilutive,” as noted in commentary in the Q3 2025 earnings coverage on Investing.com (Nov 3 2025). That’s not a base case today given the net cash balance, but it’s not a theoretical risk either if growth stalls while spending continues.

How We’d Approach HIMS Position Sizing Right Now

Putting it all together, here’s how we at DeepValue are thinking about HIMS in a portfolio context.

Our current stance: WAIT with defined triggers

We are not buyers at current levels, but we also don’t see this as an obvious short given the cash balance, real profitability, and optionality around Labs and platform expansion.

Instead, we anchor on a set of price levels and data triggers:

Attractive Entry: Around $22 or below

This is where the risk/reward starts to look more interesting if fundamentals hold.

Trim Above: Around $34

If the stock re-rates toward our bull-case value without fundamental confirmation, we’d be inclined to trim or avoid adding.

Re-Assessment Window: The next 3–6 months (Q1–Q2 2026)

This is when we expect key data on post-shortage GLP-1 demand, marketing efficiency, Labs attach, and margin durability.

We’d increase conviction if:

ARPU stays near $80
Adjusted EBITDA margin remains ≥12%
Marketing ≤39% of revenue with sequential subscriber adds >50k

We’d decrease conviction if:

ARPU drops below $70
Adjusted EBITDA margin slips under 10%
Marketing % rises, but subscriber adds fail to accelerate

In practice, that means keeping a watchlist slot or small tracking position while we wait for Q1–Q2 2026 data. Larger position sizes make more sense only if the metrics we outlined break decisively in Hims & Hers’ favor.

If you’re running a broad portfolio and trying to keep tabs on these operating KPIs across multiple names, manual tracking becomes painful fast.

Let [DeepValue](https://app.deepvalue.tech/) monitor the next 10-Qs, ingest new 8-Ks automatically, and update citation-backed KPIs like ARPU, marketing %, and subscriber growth for HIMS so you can react quickly when triggers hit.

See the Full Analysis →

Final Thoughts: What Smart Investors Should Watch Next

Hims & Hers is no longer just a GLP-1 momentum name. It’s a scaled, profitable digital-health platform with a real shot at building a durable subscription franchise across weight loss, hormones, mental health, dermatology, and diagnostics.

The bull and bear cases are both easy to articulate:

Bull case: Labs attach and diagnostics renewals lift ARPU and retention; marketing efficiency holds despite brand wars; regulatory risk remains manageable; vertical integration yields lasting cost and experience advantages.
Bear case: Compounded GLP-1 economics erode faster than new lines ramp; the marketing arms race crushes CAC/LTV; regulatory or advertising actions hit growth just as fixed costs peak; multiple contracts down from 40x earnings to something far lower.

Our role, as we see it, is to avoid being seduced by either extreme narrative. The next two quarters will provide hard evidence on which trajectory Hims & Hers is actually on.

For now, we’re comfortable with a WAIT rating:

The business is good, but the valuation is full.
The balance sheet is strong, but the regulatory path is narrowing.
The platform vision is compelling, but Labs and international still need to prove their economics.

If you follow the name, we’d suggest creating a simple watchlist of three things to track each quarter:

1. Marketing % of revenue vs. net subscriber adds

2. ARPU trajectory vs. mix shift away from compounded GLP-1s

3. Any quantitative signal from Labs attach/renewal or ARPU support

As those data points come in through Q2 and Q3 2026, you’ll be in a much better position to decide whether HIMS deserves a place as a core compounder in your portfolio—or whether it should stay a well-researched “pass.”

If you want to replicate this structured approach across your entire watchlist, not just HIMS,

Test-drive our deep research agent on HIMS and your other top ideas, and see how quickly you can move from raw SEC filings to a clear, citation-backed thesis with defined triggers and price levels.

Try DeepValue Free →

Hims & Hers Health (HIMS) Deep Research Report: Weighing Growth Hopes Against Regulatory Risks in 2026